Publications by authors named "Bo-Fang Chen"
Purpose: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy have demonstrated significant clinical benefits in progression-free and overall survival. This study investigates the outcomes associated with two kinds of CDK4/6i in patients with hormone receptor (HR)-positive metastatic and relapsed breast cancer to inform real-world evidence of treatment strategies.
Methods: This retrospective study included 340 Taiwanese patients with HR-positive advanced breast cancer from the Taipei Veterans General Hospital, between 2018 and 2023.
Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
Breast Cancer Res
December 2023
Article Synopsis
- The study focuses on the prevalence of genetic mutations in BRCA1, BRCA2, and PALB2 among Taiwanese breast cancer patients as a potential target for cancer therapy using PARP inhibitors.
- Tumor-targeted sequencing was performed on 924 samples from 879 patients, revealing that 14.8% had genetic alterations related to these genes, with notable co-occurrence of mutations among them.
- Of the identified mutations, many were novel, with a significant portion (60.2%) not previously documented, highlighting a need for continued research in genetic profiling for tailored cancer treatments.
Article Synopsis
- This study looked at a type of breast cancer called luminal B1, which has worse outcomes than another type called luminal A.
- Researchers analyzed the genetic information from patients in Taiwan to find targets for possible treatments.
- They found that certain gene changes, especially in PIK3CA, FGFR1, and BRCA1/2, were common in the more serious cases of this cancer.
In this study, we evaluated the concordance of targeted sequencing between paired ctDNA and matched tumor samples from early breast cancers treated with curative intention. Molecular profiling was performed using the Oncomine Comprehensive Assay v3 and the Oncomine Breast cfDNA Assay v2. The liquid biopsy detection rate was 39% (all-stage breast cancers, n = 612).
View Article and Find Full Text PDFPurpose: Invasive lobular cancer (ILC) is the second most common histology type of breast cancer followed by invasive ductal carcinoma (IDC). This study aimed to investigate the characteristic, treatment strategies, and clinical outcomes of ILC based on a national population-based cancer registry.
Methods: This study recruited 2671 ILC and 52,215 IDC patients diagnosed between 2011 and 2017 using the Taiwan Cancer Registry (TCR).
Background: Hormone receptor-positive, human epidermal growth factor receptor II (HER2)-negative luminal B1 breast cancer is associated with a higher risk of disease relapse than luminal A breast cancer. Therefore, we assessed and compared the distant metastasis pattern and clinical outcomes associated with luminal B1 and luminal A breast cancer in an Asian population.
Methods: In this observational study, we assessed patients with estrogen receptor-positive, HER2-negative breast cancer who underwent surgery from 2009 to 2016.